Results 11 to 20 of about 39,781 (168)
Predictors of Liver Steatosis Progression Among People Living With HIV in Low- and Middle-Income Countries: A Multicentre Longitudinal Study. [PDF]
J Int AIDS SocABSTRACT Introduction Liver steatosis is increasingly recognized as a major comorbidity in people living with HIV (PLWH), with growing evidence suggesting an increased risk of progression to advanced liver disease. We assessed predictors of liver steatosis progression over 36 months in PLWH from low‐ and middle‐income countries.
Plaisy MK +27 more
europepmc +2 more sources
Frontiers in Microbiology, 2022 Integrase strand transfer inhibitor (INSTI)-containing regimens in HIV-1-infected patients have experienced a global increase. Recently, WHO has emphasized the need to fast-track the transition to dolutegravir (DTG)-based antiretroviral (ARV) treatments.
Horacio Gil +5 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2020 Objectives: This study evaluated the emergence of mutations associated with integrase strand transfer inhibitors (INSTI) resistance (INSTI-RMs) and the integrase evolution in human immunodeficiency virus type 1 (HIV-1) infected patients treated with this
Rossana Scutari +14 more
doaj +1 more source
Antiviral Therapy, 2022 Background Substantial body composition alterations have been reported after starting combined antiretroviral therapy (cART). We characterized a cohort of chronically infected and virologically suppressed (VL < 50 copies/ml) men (≥50 years old) living ...
Julie K. Wisch PhD +8 more
doaj +1 more source
Demographic and HIV disease characteristics of INSTI- and non-INSTI-exposed mothers and infants.
, 2023 Demographic and HIV disease characteristics of INSTI- and non-INSTI-exposed mothers and infants.
Christiana Smith (743534) +11 more
core +1 more source
AIDS Research and Treatment, 2023 Current U.S. guidelines recommend integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) as initial treatment for people with HIV (PWH). We assessed long-term effects of INSTI use on lipid profiles in routine HIV care. We analyzed
Jun Li +11 more
doaj +1 more source
, 2022 Background and Objective: Integrase strand transfer inhibitors (INSTIs) are currently the standard of practice for first-line HIV therapy for most patients.
Akhan, Sıla +7 more
core +1 more source
Pathogens, 2022 Background: Integrase strand-transfer inhibitor (INSTI)-containing regimens have gradually been administered in Guangdong Province, China beginning in 2016, and INSTI-related drug resistance (DR) may occur and should be monitored among HIV-1-infected ...
Yun Lan +9 more
doaj +1 more source
Pregnancy outcomes of women receiving INSTI- and non-INSTI antiretroviral therapy.
, 2023 Pregnancy outcomes of women receiving INSTI- and non-INSTI antiretroviral therapy.
Christiana Smith (743534) +11 more
core +1 more source
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. [PDF]
PLoS ONE, 2017 T97A is an HIV-1 integrase polymorphism associated with integrase strand transfer inhibitor (INSTI) resistance. Using pooled data from 16 clinical studies, we investigated the prevalence of T97A (pre-existing and emergent) and its impact on INSTI ...
Michael E Abram +6 more
doaj +1 more source